PDCD1 and neoplasm: EcN/IL-15 + L combined with anti-PD-1 antibodies significantly suppressed tumor growth, achieving complete tumor rejection in 43% of mice (3/7), versus 14% (1/7) with EcN/IL-15 + L alone.